Download Unicorn Signals App

Powered By EquityPandit
Latest News

Dr Reddy’s Laboratories has launched Bivalirudin injection

Dr Reddy’s Laboratories (DRL) has launched Bivalirudin injection which is indicated for use as an anti-coagulant in patients, after getting approval from the US health regulator.

Dr Reddy’s said in a BSE filing that it has “launched Bivalirudin for injection, 250 mg/vial, a therapeutic equivalent generic version of Angiomax for injection, approved by the US Food and Drug Administration (USFDA).”

It said that its Bivalirudin injection, 250 mg/vial, is available in packages of 10 single-dose vials.

Read EquityPandit’s Technical Analysis on Nifty Pharma

Get Daily Prediction & Stocks Tips On Your Mobile